首页 | 本学科首页   官方微博 | 高级检索  
     

miR-520a-3p调控宫颈癌细胞因子分泌的信号通路
引用本文:刘红艳,鲁启洪,黄楚鹰. miR-520a-3p调控宫颈癌细胞因子分泌的信号通路[J]. 中国应用生理学杂志, 2020, 36(4): 340-345. DOI: 10.12047/j.cjap.5935.2020.073
作者姓名:刘红艳  鲁启洪  黄楚鹰
作者单位:1.湖北省恩施土家族苗族自治州中心医院 肿瘤放疗中心, 恩施 445000;2.湖北省恩施土家族苗族自治州中心医院神经内科, 恩施 445000;3.湖北省恩施土家族苗族自治州中心医院肿瘤一科, 恩施 445000
摘    要:目的:探讨miR-520a-3p调控宫颈癌细胞因子分泌的分子机制。方法:通过Target Scan Human分析miR-520a-3p与NF-κB复合体亚基RELA的匹配情况,然后通过荧光素酶报告系统检测miR-520a-3p是否靶向NF-κB复合体亚基RELA;使用LPS刺激宫颈癌HELA细胞后,将miR-520a-3p mimics与转染试剂混合后滴入HELA细胞中,此为过表达组;将miR-520a-3p inhibitor与转染试剂混合后滴入HELA细胞中,此为敲低组,通过酶联免疫吸附试验检测过表达组和敲低组GCSF,GM-CSF,IL-2,IL-3,IL-4,IL-5,IL-6,IL-9,IL-10,IL-12 p40,IL-12 p70,IL-13,IL-17,IFN-γ,MCP-1,MCP-5,RANTES,TNFα的表达水平。每次实验重复3次。结果:miR-520a-3p靶向RELA的3’UTR; LPS激活NF-kB信号通路后,宫颈癌HELA细胞分泌的细胞因子GCSF,GM-CSF,IL-2,IL-3,IL-4,IL-5,IL-6,IL-9,IL-10,IL-12 p...

关 键 词:miR-520a-3p  NF-kB  宫颈癌HELA细胞  细胞因子
收稿时间:2019-09-09

miR-520a-3p regulates the signaling pathway of cytokine secretion in cervical cancer
LIU Hong-yan,LU Qi-hong,HUANG Chu-ying. miR-520a-3p regulates the signaling pathway of cytokine secretion in cervical cancer[J]. Chinese journal of applied physiology, 2020, 36(4): 340-345. DOI: 10.12047/j.cjap.5935.2020.073
Authors:LIU Hong-yan  LU Qi-hong  HUANG Chu-ying
Affiliation:1. Tumor Radiotherapy Center of Central Hospital of Enshi Tujia Miao Autonomous Prefecture, Hubei Province, Enshi 445000;2. CentralHospital of Enshi Tujia and Miao Autonomous Prefecture, Hubei Province, Department of Neurology, Enshi 445000;3. Department of Oncology, Central Hospital of Enshi Tujia and Miao Autonomous Prefectures, Hubei Province, Enshi 445000, China
Abstract:Objective: To investigate the molecular mechanism of miR-520a-3p regulating the secretion of cytokines in cervical cancer. Methods: The matching between miR-520a-3p and the NF-κB complex subunit RELA was analyzed by TargetScanHuman, and then the luciferase reporting system was used to detect whether miR-520a-3p targeted the NF-κB complex subunit RELA. After cervical cancer HELA cells stimulated by LPS, in the overexpression group or the knockout group, miR-520a-3p mimics or inhibitor were mixed with transfection reagent and dripped into HELA cells. The expression levels of colony stimulating factor (GCSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin 2 (IL-2), interleukin 3 (IL-3), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 19 (IL-9), interleukin 10 (IL-10), interleukin 12 p40 (IL-12 p40), interleukin 12 p70 (IL-12 p70), interleukin 13 (IL-13), interleukin 17 (IL-17), interferon gamma (IFN-γ), monocyte chemoattractant protein-1 (MCP-1), monocyte chemoattractant protein-5 (MCP-5), small inducible cytokine A5 (RANTES), tumor necrosis factor-alpha (TNFα) were detected by enzyme-linked immunosorbent assay in both the overexpression group and the knockout group. Each experiment was repeated three times. Results: miR-520a-3p targeted the 3’UTR of RELA. After activation of the NF-κB signaling pathway by lipopolysaccharide (LPS), the protein expression levels of cytokines GCSF, GM-CSF, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 p40, IL-12 p70, IL-13, IL-17, IFN-γ, MCP-1, MCP-5, RANTES, TNFα secreted by HELA cells of cervical cancer were increased significantly (P<0.05). In the overexpression group, the protein expression level of RELA of NF-κB complex subunit was decreased, and the protein expression level of the above-mentioned cytokines secreted by HELA cells of cervical cancer were decreased (P<0.05). In the knockdown group, the protein expression level of RELA, a subunit of NF-κB complex, and the protein expression level of the above-mentioned cytokines secreted by HELA cells of cervical cancer were increased (P<0.05). Conclusion: miR-520a-3p inhibits cytokine secretion in HELA cells of cervical cancer by targeting RELA, a key molecule in the NF-κB signaling pathway.
Keywords:miR-520a-3p  NF-κB  HELA cells of cervical cancer  cytokines  
本文献已被 CNKI 等数据库收录!
点击此处可从《中国应用生理学杂志》浏览原始摘要信息
点击此处可从《中国应用生理学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号